-
Top 4 Stocks In The Drug Delivery Industry With The Highest Operating Margin
Friday, June 10, 2011 - 12:53am | 131Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at Valeant Pharmaceuticals International Inc (NYSE: VRX) is 27.84%. VRX's revenue for the same period is $1.53 billion. The trailing-twelve-month operating...
-
Stock Picks and Trade Ideas for Friday, June 10
Thursday, June 9, 2011 - 5:04pm | 1789( click to enlarge ) Elan Corporation, plc (ADR) (NYSE:ELN) broke out today and traded nearly 2x normal daily volume. The stock has the potential to make a big run on Friday, so keep a close eye on ELN and don't miss the trade. From the technical analysis perspective, the outlook for Elan...
-
Five Investments for Johnny Depp's Birthday
Thursday, June 9, 2011 - 1:45pm | 559Johnny Depp is the most beloved, beautiful actor of his generation. He has starred in everything from small-budget art pieces to blockbuster cinema movies. His eyes are synonymous with sex for a lot of folks in the 25-50 age group. Today happens to be Depp's 48th (already?) birthday. In his honor,...
-
Duncan Williams Maintains Obagi Medical Products Hold
Thursday, June 9, 2011 - 1:15pm | 73Duncan Williams maintained its Obagi Medical Products (NASDAQ: OMPI) Hold rating in a research report published today. In the report, Duncan Williams states, "We are still not certain if the Texas issue is isolated or the beginning of more HQ caution (as we noted for internet retailers)." Shares...
-
Synthes and Eli Lilly Sign Development and Collaboration Agreement
Thursday, June 9, 2011 - 11:30am | 121Synthes, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures. The agreement allows for the...
-
Patients Reported Improvement in Motor Symptoms in Abbott's Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
Thursday, June 9, 2011 - 9:32am | 153Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's (NYSE: ABT) investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel for 12 weeks reported a decrease in "off" time and an...
-
Oppenheimer Maintains Outperform on Somaxon Pharmaceuticals
Thursday, June 9, 2011 - 9:17am | 136Oppenheimer is out with its report today on Somaxon Pharmaceuticals (NASDAQ: SOMX), maintaining Outperform. In a note to clients, Oppenheimer writes, "Our investment thesis is based primarily on the potential of Silenor, SOMX's recently approved product for treatment of insomnia. In particular, we...
-
Elan Jumping Nearly 6% On Biogen Rumors
Thursday, June 9, 2011 - 8:40am | 93Elan Corporation, plc (NYSE: ELN) shares are soaring this morning on rumors that Biogen Idec (NASDAQ: BIIB) may bid for the company. Just the other day, Biogen said that it would be looking for deals to expand its portfolio of multiple sclerosis drugs, and Biogen has partnered with Elan on an MS...
-
Marina Biotech Completes Dosing of First Cohort in the Phase 1b/2a START-FAP Clinical Trial of CEQ508
Thursday, June 9, 2011 - 8:36am | 108Marina Biotech, Inc. (NASDAQ: MRNA) today announced the completion of dosing for Cohort 1 in the Dose Escalation Phase of its START-FAP clinical trial with CEQ508. The first three patients received the starting dose of 1x10(8) colony forming units (cfu)/day for up to 28 days of continuous oral...
-
Benzinga's Top Pre-Market NASDAQ Losers
Thursday, June 9, 2011 - 8:23am | 140Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) dipped 5.91% to $50 in the pre-market session. VRTX reported interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat...
-
Stocks to Watch: Fresh 52-Week Highs and Lows
Thursday, June 9, 2011 - 4:33am | 823The following stocks hit new 52-week highs in Wednesday's trading session: 1) 8x8 (NASDAQ: EGHT): Shares of 8x8 hit a 52-week high of $3.97 in Wednesday's session. The stock was heavily sold into, however, finishing 7.7% lower on the day at $3.48. The year-to-date performance of 8x8 is a gain of...
-
UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
Wednesday, June 8, 2011 - 4:57pm | 181Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) today issued the following statement regarding the decision of the United States District Court for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company (NYSE: LLY) from engaging in...
-
U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation
Wednesday, June 8, 2011 - 4:18pm | 83Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals (NASDAQ: AMLN) for a preliminary injunction that sought to impose...
-
Options Brief: Amarin Corporation
Wednesday, June 8, 2011 - 12:57pm | 67Shares of Amarin Corporation (NASDAQ: AMRN) are higher on the session by 2.11%, trading at $16.26. Overall call volume is now running at 2.07x the daily average, with 28% of all calls traded being purchases on the offer. 19,679 contracts have traded on the session so far. Amarin Corporation plc...
-
Goldman Sachs Suggests Buying Puts on Bristol-Myers Squibb
Wednesday, June 8, 2011 - 9:43am | 150Goldman Sachs is out with a research report this morning, where is suggests that traders buy puts on Bristol-Myers Squibb (NYSE: BMY) to hedge their long exposure to the name. Goldman Sachs Pharma analyst, Jami Rubin, recently downgraded BMY to Neutral and sees upcoming ARISTOTLE results to be...